Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!

On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.

Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.

In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.

Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/

CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/

MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#FieldTripHealth #Cybin #Mydecine

The mental healthcare crisis is escalating: Are Psychedelic Medicines the Solution? Can psychedelics health North America fight against anxiety, depression and addiction?

It is well known that during these unprecedented times of lockdowns and fear, our society’s mental health has taken a toll. Unfortunately, few realize how dire the situation has become.
In some respects, this pandemic has accelerated other health care crises: such as the addiction and overdose crisis, the depression crisis, and the anxiety crisis.
These crises can be hard to see when the illnesses are often hidden by those that are experiencing them, out of shame.

However, we can’t start talking about solutions to the problem until we see how big the problem is.
Therefore, in this episode, we are going to take a look at:
1. Some of the data regarding addiction, depression, and anxiety levels during the pandemic, and show you how stark this increase has been;

2. We will discuss a novel solution which has a lot of evidence backing it up: using psychedelics like magic mushrooms and LSD to treat these maladies of the mind;

Enjoy the episode!

Timestamps:
0:00 – Intro
1:37 – Increased rates of Anxiety, Depression & Addiction in North America
6:24 – Psychedelic inspired medicines – potential solutions?

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Links:
Rates of addiction since the epidemic began:
https://www.kten.com/story/44309290/continued-increase-in-substance-abuse-after-pandemic

Rates of overdose:
https://www.google.com/url?q=https://www.forbes.com/sites/niallmccarthy/2021/07/16/us-experiences-a-historic-spike-in-overdose-deaths-infographic/?sh5452ed443650&sa=D&source=editors&ust=1626828792173000&usg=AOvVaw3NuNLOX7F8X_pg9Uh0Rnhv

Rates of depression:
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.nature.com/articles/d41586-021-00175-z

Research into psychedelics as potential alternative treatments

Psilocybin: A potential treatment for depression:
https://newatlas.com/health-wellbeing/psilocybin-therapy-major-depression-trial-results-johns-hopkins/
https://www.imperial.ac.uk/news/219413/magic-mushroom-compound-performs-well-antidepressant/

Psilocybin : A potential cure for Smoking:
https://pubmed.ncbi.nlm.nih.gov/27441452/

Ibogaine: A potential cure for addiction:
https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#ANXIETY#DEPRESSION #PsychedelicTherapy

HUGE UPDATE: Compass Pathways, (NASDAQ: CMPS), completes the LARGEST Phase 2b psilocybin clinical study to treat treatment resistant depression (TRD).

This is the most important psychedelic therapy study that we know of because it is both the largest clinical trial testing psilocybin to date and it is also the most advanced in the clinical trial process.

In this episode we will discuss:
– The details of this trial and why it is so important;
– The big update that we have for you;
– When we can expect results;
– Where the field goes from here in the near future.

Timestamps:

0:00 – Intro
1:31 – What is Compass Pathways’ Phase2b trial and why is it important?
6:57 – The major Update on CMPS’ Clinical Trial
8:07 – Anticipated results date & what these results will mean for the psychedelic industry

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#CompassPathways #CMPS #PsychedelicTherapy

Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That’s why we decided to invite NUMI’s CEO, Payton Nyquvest. I hope you all enjoy!

Timestamps
1:00 – What is Numinus’ mission?
2:37 – Numinus’ partnership with MAPS to treat PTSD with MDMA
9:54 – Numinus treating addiction with Psilocybin
13:35 – Using ketamine to treat Depression
18:45 – Growing natural Psilocybin vs Synthetic versions?
21:45 -The 5-year plan
26:38 – What will revenues look like?

Enjoy the episode!

Check out our website:
ThePsychedelicInvestor.com

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #NUMIStock
#numinus #numi #numistock